In fact, the marker genes of the GABRA receptor families and cystine transporter xCT (SLA7A11 and CD44v), as well as antioxidation-controlled factors, such as JDP2, NRF2, and CDKN1A (p21Cip1), were significantly mutated in brain tumors, e.g., glioblastoma, glioma, and neuroblastoma (Fig. S4A, B). This evidence concerns the gene CDKN1A and central nervous system cancer.